SCHEMBL3013102

SCHEMBL3013102

Cc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4cc(F)cc(F)c4)cs3)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DNM1L O00429 7/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
KCNH2 Q12809 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006901 0.94 GBA1 (0.39) GBA1SMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL3020046 0.93 HTR2A (0.42) SMN1; SMN2MAPTALDH1A1NPC1RAB9A
SCHEMBL3022765 0.91 GBA1 (0.42) GBA1SMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL3016061 0.91 GBA1 (0.43) GBA1SMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL3019220 0.90 SMN1; SMN2 (0.40) GBA1SMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL3016374 0.90 SMN1; SMN2 (0.37) SMN1; SMN2MAPTALDH1A1CYP1A2CYP2C9
SCHEMBL3015772 0.90 HTR2A (0.44) SMN1; SMN2MAPTALDH1A1CYP1A2CYP2C9
SCHEMBL3017469 0.90 GBA1 (0.45) GBA1SMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL3006919 0.90 ALDH1A1 (0.35) GBA1SMN1; SMN2MAPTALDH1A1DNM1L
SCHEMBL3013242 0.89 HTR2A (0.35) GBA1SMN1; SMN2MAPTALDH1A1DNM1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.